Cue Biopharma has appointed James Ahlers as Chief Financial Officer, effective immediately. Ahlers brings more than 25 years of financial leadership experience from public and private biotechnology companies, most recently serving as a consulting CFO and strategic advisor to Intensity Therapeutics, RenovoRx, Arsenal Biosciences, and RegCell. He will report to President and CEO Shao-Lee Lin and oversee financial leadership as the company advances its clinical pipeline, which includes a recently submitted Investigational New Drug application for CUE-221 in food allergy and expected Phase 2 data for its chronic spontaneous urticaria program by the end of the current quarter. Cue Biopharma shares closed Monday at $26.87, up 0.11%.
Cue BiopharmaAppointment of new CFO is a management change with no direct impact on operations or financials.
Intensity Therapeutics, Inc. Common stock
RenovoRx Inc